Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Aim

This review has examined and organized the available research on dementia medication care costs. Although the accessible database in this area is growing and is still quite limited, there are many clear scientific methods.

Objective

The use of Memantine, a non-competitive antagonist with low to moderate affinity for the NMDA (N-methyl-D-aspartate) receptor, has been approved for the treatment of mild to moderately severe Alzheimer's disease (AD). The efficacy of cholinesterase inhibitors (ChEIs) in the treatment of dementia varies depending on the drug type and ease of administration. Numerous techniques have been employed to evaluate the quality of life (QOL) of individuals suffering from dementia. QOL data is a well-established measure of an intervention's effectiveness. Up to now, cost-effectiveness studies have concentrated on both pharmaceutical and non-pharmacological therapy. Each unit of QoL-AD improvement costs USD27.82578 at mean values.

Methods

Searches were conducted to observe studies of the pharmacoeconomic impact of dementia medications with the help of previous articles published in journals and collected from Google Scholar with name search dementia or Alzheimer's cross-referenced with pharmacoeconomic costs and effectiveness.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X259911231128112915
2023-12-08
2024-12-27

  • From This Site

    /content/journals/cis/10.2174/012210299X259911231128112915
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/2/1/CIS-2-E2210299X259911.html?itemId=/content/journals/cis/10.2174/012210299X259911231128112915&mimeType=html&fmt=ahah

References

  1. YingQ. XingX. LiuL. LinA-L. JacobsN. LiangG. Multi-modal data analysis for alzheimer’s disease diagnosis: An ensemble model using imagery and genetic features. Ying, Q.; Xing, X.; Liu, L.; Lin, A-L.; Jacobs, N.; Liang, G., Eds.;2021 43rd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)2021IEEE
     [Google Scholar]
  2. KoenigL.N. LaMontagneP. GlasserM.F. BatemanR. HoltzmanD. YakushevI. ChhatwalJ. DayG.S. JackC. MummeryC. PerrinR.J. GordonB.A. MorrisJ.C. ShimonyJ.S. BenzingerT.L.S. Dominantly Inherited Alzheimer Network (DIAN) Regional age-related atrophy after screening for preclinical Alzheimer disease.Neurobiol. Aging2022109435110.1016/j.neurobiolaging.2021.09.01034655980
     [Google Scholar]
  3. Association As 2018 Alzheimer’s disease facts and figures.Alzheimers Dement.201814336742910.1016/j.jalz.2018.02.001
     [Google Scholar]
  4. WinbladB. AmouyelP. AndrieuS. BallardC. BrayneC. BrodatyH. Cedazo-MinguezA. DuboisB. EdvardssonD. FeldmanH. FratiglioniL. FrisoniG.B. GauthierS. GeorgesJ. GraffC. IqbalK. JessenF. JohanssonG. JönssonL. KivipeltoM. KnappM. MangialascheF. MelisR. NordbergA. RikkertM.O. QiuC. SakmarT.P. ScheltensP. SchneiderL.S. SperlingR. TjernbergL.O. WaldemarG. WimoA. ZetterbergH. Defeating Alzheimer’s disease and other dementias: a priority for European science and society.Lancet Neurol.201615545553210.1016/S1474‑4422(16)00062‑426987701
     [Google Scholar]
  5. Sachs-EricssonN. BlazerD.G. The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment.Aging Ment. Health201519121210.1080/13607863.2014.92030324914889
     [Google Scholar]
  6. VuicB. KonjevodM. TudorL. MilosT. Nikolac PerkovicM. Nedic ErjavecG. PivacN. UzunS. MimicaN. Svob StracD. Tailoring the therapeutic interventions for behavioral and psychological symptoms of dementia.Expert Rev. Neurother.202222870772010.1080/14737175.2022.211266835950234
     [Google Scholar]
  7. DichterM.N. QuasdorfT. SchwabC.G.G. TrutschelD. HaastertB. RiesnerC. BartholomeyczikS. HalekM. Dementia care mapping: Effects on residents’ quality of life and challenging behavior in German nursing homes. A quasi-experimental trial.Int. Psychogeriatr.201527111875189210.1017/S104161021500092726138674
     [Google Scholar]
  8. MukadamN. AndersonR. KnappM. WittenbergR. KaragiannidouM. CostafredaS.G. TuttonM. AlessiC. LivingstonG. Effective interventions for potentially modifiable risk factors for late-onset dementia: A costs and cost-effectiveness modelling study.Lancet Healthy Longev.202011e13e2010.1016/S2666‑7568(20)30004‑036094185
     [Google Scholar]
  9. WangG. AlbayrakA. van der CammenT.J.M. A systematic review of non-pharmacological interventions for BPSD in nursing home residents with dementia: From a perspective of ergonomics.Int. Psychogeriatr.20193181137114910.1017/S104161021800167930334500
     [Google Scholar]
  10. van der FlierW.M. ScheltensP. Epidemiology and risk factors of dementia.J. Neurol. Neurosurg. Psychiatry200576Suppl 5Suppl. 5v2v710.1136/jnnp.2005.08286716291918
     [Google Scholar]
  11. QuentinW. Riedel-HellerS.G. LuppaM. RudolphA. KönigH.H. Cost-of-illness studies of dementia: A systematic review focusing on stage dependency of costs.Acta Psychiatr. Scand.2010121424325910.1111/j.1600‑0447.2009.01461.x19694634
     [Google Scholar]
  12. GridleyK. BrooksJ. BirksY. BaxterK. ParkerG. Improving care for people with dementia: Development and initial feasibility study for evaluation of life story work in dementia care.Health Serv. Deliv. Res.2016423129810.3310/hsdr0423027559566
     [Google Scholar]
  13. JesteD.V. BlazerD. CaseyD. MeeksT. SalzmanC. SchneiderL. TariotP. YaffeK. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia.Neuropsychopharmacology200833595797010.1038/sj.npp.130149217637610
     [Google Scholar]
  14. BassilN. GrossbergG.T. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer’s disease.CNS Drugs200923429330710.2165/00023210‑200923040‑0000319374459
     [Google Scholar]
  15. FortunatoS. ForliF. GuglielmiV. De CorsoE. PaludettiG. BerrettiniS. FetonIA.R. A review of new insights on the association between hearing loss and cognitive decline in ageing.Acta Otorhinolaryngol. Ital.201636315516610.14639/0392‑100X‑99327214827
     [Google Scholar]
  16. HaakeA. NguyenK. FriedmanL. ChakkamparambilB. GrossbergG.T. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease.Expert Opin. Drug Saf.202019214715710.1080/14740338.2020.172145631976781
     [Google Scholar]
  17. CooperC. LodwickR. WaltersK. RaineR. ManthorpeJ. IliffeS. PetersenI. Observational cohort study: Deprivation and access to anti-dementia drugs in the UK.Age Ageing201645114815410.1093/ageing/afv15426582758
     [Google Scholar]
  18. SchneiderL.S. DagermanK.S. HigginsJ.P. McShaneR. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.Arch. Neurol.201168899199810.1001/archneurol.2011.6921482915
     [Google Scholar]
  19. SchneiderL.S. MangialascheF. AndreasenN. FeldmanH. GiacobiniE. JonesR. MantuaV. MecocciP. PaniL. WinbladB. KivipeltoM. Clinical trials and late-stage drug development for A lzheimer’s disease: an appraisal from 1984 to 2014.J. Intern. Med.2014275325128310.1111/joim.1219124605808
     [Google Scholar]
  20. MatsunagaS. KishiT. IwataN. Memantine monotherapy for Alzheimer’s disease: A systematic review and meta-analysis.PLoS One2015104e012328910.1371/journal.pone.012328925860130
     [Google Scholar]
  21. KeiskiM. Memantine: A safe and tolerable NMDA antagonist with potential benefits in traumatic brain injury.New therapeutics for traumatic brain injury.2017253271
     [Google Scholar]
  22. ValisM. HermanD. VanovaN. MasopustJ. VysataO. HortJ. PavelekZ. KlimovaB. KucaK. MisikJ. Zdarova KarasovaJ. The concentration of memantine in the cerebrospinal fluid of Alzheimer’s disease patients and its consequence to oxidative stress biomarkers.Front. Pharmacol.20191094310.3389/fphar.2019.0094331555132
     [Google Scholar]
  23. WinbladB. JonesR.W. WirthY. StöfflerA. MöbiusH.J. Memantine in moderate to severe Alzheimer’s disease: A meta-analysis of randomised clinical trials.Dement. Geriatr. Cogn. Disord.2007241202710.1159/00010256817496417
     [Google Scholar]
  24. NakamuraY. KitamuraS. HommaA. ShiosakaiK. MatsuiD. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer’s disease: Results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.Expert Opin. Pharmacother.201415791392510.1517/14656566.2014.90244624673497
     [Google Scholar]
  25. RinneJ.O. WesnesK. CummingsJ.L. HakulinenP. HallikainenM. HänninenJ. MurphyM. RiordanH. ScheininM. SoininenH. RouruJ. Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer’s disease.Alzheimers Dement. (N. Y.)2017311910.1016/j.trci.2016.11.00429067315
     [Google Scholar]
  26. PerryG. LeeH. LeeH.P. ZhuX. SmithM.A. RolstonR.K. MarlattM.W. CastellaniR.J. NunomuraA. CasadesusG. ClarkT.A. Oxidative stress and its implications for future treatments and management of Alzheimer disease.Int. J. Biomed. Sci.20106322522710.59566/IJBS.2010.622521765811
     [Google Scholar]
  27. BondM. RogersG. PetersJ. AndersonR. HoyleM. MinersA. MoxhamT. DavisS. ThokalaP. WailooA. JeffreysM. HydeC. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): A systematic review and economic model.Health Technol. Assess.20121621147010.3310/hta1621022541366
     [Google Scholar]
  28. Bezerra da SilvaC. PottA. Elifio-EspositoS. DalarmiL. Fialho do NascimentoK. Moura BurciL. de OliveiraM. de Fátima Gaspari DiasJ. Maria Warumby ZaninS. Gomes MiguelO. Dallarmi MiguelM. Effect of donepezil, tacrine, galantamine and rivastigmine on acetylcholinesterase inhibition in Dugesia tigrina.Molecules20162115310.3390/molecules2101005326760993
     [Google Scholar]
  29. FerrisS. FarlowM. Language impairment in Alzheimer’s disease and benefits of acetylcholinesterase inhibitors.Clin. Interv. Aging201381007101410.2147/CIA.S3995923946647
     [Google Scholar]
  30. StefanacciR.G. The costs of Alzheimer’s disease and the value of effective therapies.Am. J. Manag. Care20111713Suppl. 13S356S36222214393
     [Google Scholar]
  31. OrrellM. YatesL.A. BurnsA. RussellI. WoodsR.T. HoareZ. Moniz-CookE. HendersonC. KnappM. SpectorA. OrgetaV. Individual cognitive stimulation therapy for dementia (iCST): Study protocol for a randomized controlled trial.Trials201213117210.1186/1745‑6215‑13‑17222998983
     [Google Scholar]
  32. ChristopherM. HolwegM. Supply chain 2.0 revisited: A framework for managing volatility-induced risk in the supply chain.Int. J. Phys. Distrib. Logist. Manag.201747121710.1108/IJPDLM‑09‑2016‑0245
     [Google Scholar]
  33. NoyesK. HollowayR.G. Evidence from cost-effectiveness research.NeuroRx20041334835510.1602/neurorx.1.3.34815717037
     [Google Scholar]
  34. KnappM. ThorgrimsenL. PatelA. SpectorA. HallamA. WoodsB. OrrellM. Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis.Br. J. Psychiatry2006188657458010.1192/bjp.bp.105.01056116738349
     [Google Scholar]
  35. MeadsD.M. MartinA. GriffithsA. KelleyR. CreeseB. RobinsonL. McDermidJ. WalwynR. BallardC. SurrC.A. Cost-effectiveness of dementia care mapping in care-home settings: Evaluation of a randomised controlled trial.Appl. Health Econ. Health Policy202018223724710.1007/s40258‑019‑00531‑131701483
     [Google Scholar]
  36. CohenD.J. ReynoldsM.R. Interpreting the results of cost-effectiveness studies.J. Am. Coll. Cardiol.200852252119212610.1016/j.jacc.2008.09.01819095128
     [Google Scholar]
  37. PrinceM BryceR AlbaneseE WimoA RibeiroW FerriCP The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer's & dementia.Alzheimers Dement.2013916375e210.1016/j.jalz.2012.11.007
     [Google Scholar]
  38. GunningbergL. HommelA. BååthC. IdvallE. The first national pressure ulcer prevalence survey in county council and municipality settings in Sweden.J. Eval. Clin. Pract.201319586286710.1111/j.1365‑2753.2012.01865.x22640165
     [Google Scholar]
  39. ZucchellaC. SinforianiE. TamburinS. FedericoA. MantovaniE. BerniniS. CasaleR. BartoloM. The multidisciplinary approach to Alzheimer’s disease and dementia. A narrative review of non-pharmacological treatment.Front. Neurol.20189105810.3389/fneur.2018.0105830619031
     [Google Scholar]
  40. ShanbhagS. DahiyaM. CroucherR. The impact of periodontal therapy on oral health-related quality of life in adults: A systematic review.J. Clin. Periodontol.201239872573510.1111/j.1600‑051X.2012.01910.x22694297
     [Google Scholar]
  41. HarrisonJ.K. Noel-StorrA.H. DemeyereN. ReynishE.L. QuinnT.J. Outcomes measures in a decade of dementia and mild cognitive impairment trials.Alzheimers Res. Ther.2016814810.1186/s13195‑016‑0216‑827866472
     [Google Scholar]
  42. SmithS. LampingD. BanerjeeS. HarwoodR. FoleyB. SmithP. CookJ. MurrayJ. PrinceM. LevinE. MannA. KnappM. Measurement of health-related quality of life for people with dementia: Development of a new instrument (DEMQOL) and an evaluation of current methodology.Health Technol. Assess.2005910193, iii-iv10.3310/hta910015774233
     [Google Scholar]
  43. AndrieuS. ColeyN. RollandY. CantetC. ArnaudC. GuyonnetS. NourhashemiF. GrandA. VellasB. PLASA group Assessing Alzheimer’s disease patients’ quality of life: Discrepancies between patient and caregiver perspectives.Alzheimers Dement.201612442743710.1016/j.jalz.2015.09.00326602086
     [Google Scholar]
  44. DuongS PatelT ChangF. Dementia: What pharmacists need to know. Can Pharm J20171502118129
     [Google Scholar]
  45. BorsonS. FrankL. BayleyP.J. BoustaniM. DeanM. LinP.J. McCartenJ.R. MorrisJ.C. SalmonD.P. SchmittF.A. StefanacciR.G. MendiondoM.S. PeschinS. HallE.J. FillitH. AshfordJ.W. Improving dementia care: The role of screening and detection of cognitive impairment.Alzheimers Dement.20139215115910.1016/j.jalz.2012.08.00823375564
     [Google Scholar]
  46. KimS.K. ParkM. Effectiveness of person-centered care on people with dementia: A systematic review and meta-analysis.Clin. Interv. Aging20171238139710.2147/CIA.S11763728255234
     [Google Scholar]
  47. CooperC. MukadamN. KatonaC. LyketsosC.G. AmesD. RabinsP. EngedalK. de Mendonça LimaC. BlazerD. TeriL. BrodatyH. LivingstonG. World Federation of Biological Psychiatry – Old Age Taskforce Systematic review of the effectiveness of non-pharmacological interventions to improve quality of life of people with dementia.Int. Psychogeriatr.201224685687010.1017/S104161021100261422244371
     [Google Scholar]
  48. BowlingA. RoweG. AdamsS. SandsP. SamsiK. CraneM. JolyL. ManthorpeJ. Quality of life in dementia: A systematically conducted narrative review of dementia-specific measurement scales.Aging Ment. Health2015191133110.1080/13607863.2014.91592324881888
     [Google Scholar]
  49. MoyleW. FetherstonhaughD. GrebenM. BeattieE. AusQoL group Influencers on quality of life as reported by people living with dementia in long-term care: A descriptive exploratory approach.BMC Geriatr.20151515010.1186/s12877‑015‑0050‑z25903463
     [Google Scholar]
  50. Sosa-OrtizA.L. Acosta-CastilloI. PrinceM.J. Epidemiology of dementias and Alzheimer’s disease.Arch. Med. Res.201243860060810.1016/j.arcmed.2012.11.00323159715
     [Google Scholar]
  51. WimoA. JönssonL. WinbladB. An estimate of the worldwide prevalence and direct costs of dementia in 2003.Dement. Geriatr. Cogn. Disord.200621317518110.1159/00009073316401889
     [Google Scholar]
  52. OxfordAE StewartES RohnTT Clinical trials in Alzheimer’s disease: a hurdle in the path of remedy.Int. J. Alzheimer's Dis.2020202010.1155/2020/5380346
     [Google Scholar]
  53. SchneiderL.S. A critical review of cholinesterase inhibitors as a treatment modality in Alzheimer’s disease.Dialogues Clin. Neurosci.2022
     [Google Scholar]
  54. 2022Evidence and Experience in Psychiatry Available at: https://epdf.tips/dementia0b8ab5cd318021def4e1645b3d82f03a61615.html
/content/journals/cis/10.2174/012210299X259911231128112915
Loading
Cost-effectiveness of Dementia Medication
Curr. Indian Sci. 2, E2210299X259911 (2024); https://doi.org/10.2174/012210299X259911231128112915
/content/journals/cis/10.2174/012210299X259911231128112915
/content/journals/cis/10.2174/012210299X259911231128112915
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alzheimer's disease (AD); Cholinesterase inhibitors (ChEIs); Cost-effectiveness; Dementia; MMSE (Mini-Mental State Examination); NMDA (N-methyl-D-aspartate); Quality of life (QOL)

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test